These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15897249)

  • 1. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
    Azrak RG; Yu J; Pendyala L; Smith PF; Cao S; Li X; Shannon WD; Durrani FA; McLeod HL; Rustum YM
    Mol Cancer Ther; 2005 May; 4(5):843-54. PubMed ID: 15897249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
    Bhattacharya A; Tóth K; Durrani FA; Cao S; Slocum HK; Chintala S; Rustum YM
    Neoplasia; 2008 Aug; 10(8):857-65. PubMed ID: 18670644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
    Yin MB; Li ZR; Tóth K; Cao S; Durrani FA; Hapke G; Bhattacharya A; Azrak RG; Frank C; Rustum YM
    Oncogene; 2006 Apr; 25(17):2509-19. PubMed ID: 16518418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
    Bhattacharya A; Tóth K; Mazurchuk R; Spernyak JA; Slocum HK; Pendyala L; Azrak R; Cao S; Durrani FA; Rustum YM
    Clin Cancer Res; 2004 Dec; 10(23):8005-17. PubMed ID: 15585636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Chintala S; Tóth K; Cao S; Durrani FA; Vaughan MM; Jensen RL; Rustum YM
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):899-911. PubMed ID: 20066420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S; Durrani FA; Rustum YM
    Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
    Azrak RG; Cao S; Pendyala L; Durrani FA; Fakih M; Combs GF; Prey J; Smith PF; Rustum YM
    Biochem Pharmacol; 2007 May; 73(9):1280-7. PubMed ID: 17239826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.
    Guo B; Cao S; Tóth K; Azrak RG; Rustum YM
    Clin Cancer Res; 2000 Feb; 6(2):718-24. PubMed ID: 10690558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
    Azrak RG; Cao S; Slocum HK; Tóth K; Durrani FA; Yin MB; Pendyala L; Zhang W; McLeod HL; Rustum YM
    Clin Cancer Res; 2004 Feb; 10(3):1121-9. PubMed ID: 14871992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
    Azrak RG; Cao S; Durrani FA; Toth K; Bhattacharya A; Rustum YM
    Cancer Lett; 2011 Dec; 311(2):219-29. PubMed ID: 21872389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
    Bhattacharya A; Seshadri M; Oven SD; Tóth K; Vaughan MM; Rustum YM
    Clin Cancer Res; 2008 Jun; 14(12):3926-32. PubMed ID: 18559614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
    Cao S; Durrani FA; Tóth K; Rustum YM
    Br J Cancer; 2014 Apr; 110(7):1733-43. PubMed ID: 24619073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antitumor activity of capecitabine in combination with irinotecan.
    Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
    Hapke G; Yin MB; Wu J; Frank C; Rustum YM
    Int J Oncol; 2002 Nov; 21(5):1059-66. PubMed ID: 12370755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
    Fakih M; Cao S; Durrani FA; Rustum YM
    Clin Colorectal Cancer; 2005 Jul; 5(2):132-5. PubMed ID: 16098255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
    Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
    Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced 7-ethyl-10-hydroxycamptothecin (SN-38) lethality by methylselenocysteine is associated with Chk2 phosphorylation at threonine-68 and down-regulation of Cdc6 expression.
    Yin MB; Li ZR; Cao S; Durrani FA; Azrak RG; Frank C; Rustum YM
    Mol Pharmacol; 2004 Jul; 66(1):153-60. PubMed ID: 15213307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
    Motwani M; Sirotnak FM; She Y; Commes T; Schwartz GK
    Cancer Res; 2002 Jul; 62(14):3950-5. PubMed ID: 12124325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
    Nanbu T; Umemura N; Ohkoshi E; Nanbu K; Sakagami H; Shimada J
    Oncol Rep; 2018 Jan; 39(1):367-375. PubMed ID: 29192320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.